Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2016

21.12.2015 | Research Article

Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study

verfasst von: M. Trovo, N. Giaj-Levra, C. Furlan, M. T. Bortolin, E. Muraro, J. Polesel, E. Minatel, R. Tedeschi, A. R. Filippi, F. Alongi, U. Ricardi

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess kinetics of plasmatic cytokines during radiation therapy (RT) for locally advanced and early-stage non-small cell lung cancer (NSCLC).

Methods

This prospective study was conducted on 15 early-stage NSCLC underwent to extreme hypofractionated regimen (52 Gy in 8 fractions) with stereotactic body RT (SBRT), and 13 locally advanced NSCLC underwent to radical moderated hypofractionated regimen (60 Gy in 25 fractions) with intensity modulated RT (IMRT). For patients undergoing SBRT, peripheral blood samples were collected on the first day of SBRT (TFd), the last day (TLd) and 45 days (T45d) after the end of SBRT. For patients undergoing IMRT, blood samples were collected at: TFd, 2 weeks (T2w), 4 weeks (T4w), TLd, and T45d. The following cytokines were measured: IL-1, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17A, EGF, FGF-2, INF-γ, MIP-1α, MIP-1β, TGF-α, TNF-α, and VEGF. Cytokine levels measured in different RT time and compared.

Results

No difference in baseline levels of cytokines was documented between patient radiation approaches (except for MIP-1α). For SBRT patients, a mean reduction of IL-10 and IL-17 plasma level was documented between TLd and TFd, respectively (p < 0.05). For IMRT patients, a statistically significant (p < 0.05) mean plasma level reduction was documented between T4w and TFd for all the following cytokines: IL-1, IL-1ra, IL-2, IL-12, FGF-2, MIP-1α, MIP-1β, TGF-α, TNF-α, VEGF.

Conclusions

SBRT and IMRT induce different plasmatic cytokine changes in NSCLC patients, supporting hypothesis that RT regimes of dose schedules and techniques have different impacts on the host immune response.
Literatur
1.
Zurück zum Zitat Bradley JD, El Naqua I, Drzymala RE, Trovò M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys. 2010;77:1146–50.CrossRefPubMed Bradley JD, El Naqua I, Drzymala RE, Trovò M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys. 2010;77:1146–50.CrossRefPubMed
3.
Zurück zum Zitat Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage I hisologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer. 2014;84:248–53.CrossRefPubMed Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage I hisologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer. 2014;84:248–53.CrossRefPubMed
4.
Zurück zum Zitat Curran W, Paulus R, Langer C, Komaki R, Lee JD, Hauser S, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452–60.CrossRefPubMedPubMedCentral Curran W, Paulus R, Langer C, Komaki R, Lee JD, Hauser S, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452–60.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Bearz A, Minatel E, Rumeileh IA, et al. Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer. 2013;13:513.CrossRefPubMedPubMedCentral Bearz A, Minatel E, Rumeileh IA, et al. Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer. 2013;13:513.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Faivre-Finn C. Dose escalation in lung cancer: have we gone full circle? Lancet Oncol. 2015;16:125–7.CrossRefPubMed Faivre-Finn C. Dose escalation in lung cancer: have we gone full circle? Lancet Oncol. 2015;16:125–7.CrossRefPubMed
7.
Zurück zum Zitat Trovo M, Linda A, El Naqua I, Javidan-Nejad C, Bradley J. Early and late radiographic injurie following stereotactic body radiation therapy (SBRT). Lung Cancer. 2010;69:77–85.CrossRefPubMed Trovo M, Linda A, El Naqua I, Javidan-Nejad C, Bradley J. Early and late radiographic injurie following stereotactic body radiation therapy (SBRT). Lung Cancer. 2010;69:77–85.CrossRefPubMed
8.
Zurück zum Zitat Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2011;79:147–54.CrossRefPubMed Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2011;79:147–54.CrossRefPubMed
9.
Zurück zum Zitat McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, et al. A sense of danger from radiation. Radiat Res. 2004;162:1–19.CrossRefPubMed McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, et al. A sense of danger from radiation. Radiat Res. 2004;162:1–19.CrossRefPubMed
10.
Zurück zum Zitat Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment—tumorigenesis and therapy. Nat Rev Cancer. 2005;5:867–75.CrossRefPubMed Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment—tumorigenesis and therapy. Nat Rev Cancer. 2005;5:867–75.CrossRefPubMed
11.
Zurück zum Zitat Rübe CE, Wilfert F, Uthe D, König J, Liu L, Schuck A, et al. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol. 2004;72:231–41.CrossRefPubMed Rübe CE, Wilfert F, Uthe D, König J, Liu L, Schuck A, et al. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol. 2004;72:231–41.CrossRefPubMed
12.
Zurück zum Zitat Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 2002;12(1 suppl 1):26–33.CrossRefPubMed Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 2002;12(1 suppl 1):26–33.CrossRefPubMed
13.
Zurück zum Zitat Hong ZY, Song KH, Yoon JH, Cho J, Story MD. An experimental model-based exploration of cytokines in ablative radiation-induced lung injury in vivo and in vitro. Lung. 2015;193:409–19.CrossRefPubMed Hong ZY, Song KH, Yoon JH, Cho J, Story MD. An experimental model-based exploration of cytokines in ablative radiation-induced lung injury in vivo and in vitro. Lung. 2015;193:409–19.CrossRefPubMed
14.
Zurück zum Zitat Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, et al. The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45:127–35.CrossRefPubMed Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, et al. The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45:127–35.CrossRefPubMed
15.
Zurück zum Zitat van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388–93.CrossRefPubMed van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388–93.CrossRefPubMed
16.
Zurück zum Zitat Ansher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1998;41:1029–35.CrossRef Ansher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1998;41:1029–35.CrossRef
17.
Zurück zum Zitat Ansher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:988–95.CrossRef Ansher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:988–95.CrossRef
18.
Zurück zum Zitat Chen Y, Rubin P, William J, Hernady E, Smudzin T, Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001;49:641–8.CrossRefPubMed Chen Y, Rubin P, William J, Hernady E, Smudzin T, Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001;49:641–8.CrossRefPubMed
19.
Zurück zum Zitat Bright RK. Immunology of lung cancer. In: Pass HI, Mitchel IB, Johnson DH, et al., editors. Lung cancer. Philadelphia: Lippincott W&W; 2000. p. 304–18. Bright RK. Immunology of lung cancer. In: Pass HI, Mitchel IB, Johnson DH, et al., editors. Lung cancer. Philadelphia: Lippincott W&W; 2000. p. 304–18.
20.
Zurück zum Zitat Witz IP. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res. 2006;130:125–40.CrossRefPubMed Witz IP. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res. 2006;130:125–40.CrossRefPubMed
21.
Zurück zum Zitat Travès PG, Luque A, Hortelano S. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm. 2012;2012:568783.CrossRefPubMedPubMedCentral Travès PG, Luque A, Hortelano S. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm. 2012;2012:568783.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer. 1996;16:47–59.CrossRefPubMed Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer. 1996;16:47–59.CrossRefPubMed
23.
Zurück zum Zitat Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830–42.CrossRefPubMedPubMedCentral Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830–42.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med. 2011;208(10):2005–16.CrossRefPubMedPubMedCentral Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med. 2011;208(10):2005–16.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–52.CrossRefPubMed Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–52.CrossRefPubMed
26.
Zurück zum Zitat Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.CrossRefPubMed Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.CrossRefPubMed
27.
Zurück zum Zitat Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69:348–54.CrossRefPubMed Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69:348–54.CrossRefPubMed
28.
Zurück zum Zitat Fleckenstein K, Gauter-Fleckenstein B, Jackson IL, Rabbani Z, Anscher M, Vujaskovic Z. Using biological markers to predict risk of radiation injury. Semin Radiat Oncol. 2007;17:89–98.CrossRefPubMed Fleckenstein K, Gauter-Fleckenstein B, Jackson IL, Rabbani Z, Anscher M, Vujaskovic Z. Using biological markers to predict risk of radiation injury. Semin Radiat Oncol. 2007;17:89–98.CrossRefPubMed
29.
Zurück zum Zitat Han G, Zhang H, Xie CH, Zhou YF. Th2-like immune response in radiation-induced lung fibrosis. Oncol Rep. 2011;26:383–8.PubMed Han G, Zhang H, Xie CH, Zhou YF. Th2-like immune response in radiation-induced lung fibrosis. Oncol Rep. 2011;26:383–8.PubMed
31.
Zurück zum Zitat Zeng L, O’Connor C, Zhang J, Kaplan AM, Cohen DA. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine. 2010;49:294–302.CrossRefPubMed Zeng L, O’Connor C, Zhang J, Kaplan AM, Cohen DA. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine. 2010;49:294–302.CrossRefPubMed
32.
Zurück zum Zitat De Vita F, Orditura M, Galizia G, Ciaramella F, Musicò M, Ferrigno A, et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 2000;117:365–73.CrossRefPubMed De Vita F, Orditura M, Galizia G, Ciaramella F, Musicò M, Ferrigno A, et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 2000;117:365–73.CrossRefPubMed
33.
Zurück zum Zitat Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol. 2003;24:36–43.CrossRefPubMed Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol. 2003;24:36–43.CrossRefPubMed
34.
Zurück zum Zitat Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, et al. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One. 2012;7:e39525.CrossRefPubMedPubMedCentral Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, et al. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One. 2012;7:e39525.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol. 2005;23:8748–56.CrossRefPubMed Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol. 2005;23:8748–56.CrossRefPubMed
36.
Zurück zum Zitat Neurath MF, Finotto S. The emerging role of T cell cytokines in non-small cell lung cancer. Cytokine Growth Factor Rev. 2012;23:315–22.CrossRefPubMed Neurath MF, Finotto S. The emerging role of T cell cytokines in non-small cell lung cancer. Cytokine Growth Factor Rev. 2012;23:315–22.CrossRefPubMed
37.
Zurück zum Zitat Li Y, Cao ZY, Sun B, Wang GY, Fu Z, Liu YM, et al. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther. 2011;12:610–6.CrossRefPubMed Li Y, Cao ZY, Sun B, Wang GY, Fu Z, Liu YM, et al. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther. 2011;12:610–6.CrossRefPubMed
38.
Zurück zum Zitat Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003;63:5505–12.PubMed Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003;63:5505–12.PubMed
39.
Zurück zum Zitat Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012;12:107–23.CrossRefPubMedPubMedCentral Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012;12:107–23.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Umekita Y, Ohi Y, Sagara Y, Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer. 2000;89:484–7.CrossRefPubMed Umekita Y, Ohi Y, Sagara Y, Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer. 2000;89:484–7.CrossRefPubMed
41.
Zurück zum Zitat Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;3:323–40.CrossRef Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;3:323–40.CrossRef
42.
Zurück zum Zitat Kong FM, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control. 2008;15:140–50.PubMed Kong FM, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control. 2008;15:140–50.PubMed
43.
Zurück zum Zitat Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy induced immunogenic cell death. Oncoimmunology. 2014;3:e28518.CrossRefPubMedPubMedCentral Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy induced immunogenic cell death. Oncoimmunology. 2014;3:e28518.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153.PubMedPubMedCentral Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153.PubMedPubMedCentral
45.
Zurück zum Zitat Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.CrossRefPubMedPubMedCentral Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589–602.CrossRefPubMed Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589–602.CrossRefPubMed
47.
Zurück zum Zitat Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012;177(3):311–27.CrossRefPubMed Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012;177(3):311–27.CrossRefPubMed
48.
Zurück zum Zitat Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87:21–7.CrossRefPubMedPubMedCentral Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87:21–7.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer. 2012;12:580.CrossRefPubMedPubMedCentral Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer. 2012;12:580.CrossRefPubMedPubMedCentral
Metadaten
Titel
Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study
verfasst von
M. Trovo
N. Giaj-Levra
C. Furlan
M. T. Bortolin
E. Muraro
J. Polesel
E. Minatel
R. Tedeschi
A. R. Filippi
F. Alongi
U. Ricardi
Publikationsdatum
21.12.2015
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1473-x

Weitere Artikel der Ausgabe 10/2016

Clinical and Translational Oncology 10/2016 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.